MV 833

Drug Profile

MV 833

Alternative Names: Anti-vascular endothelial growth factor monoclonal antibody - Toagosei; Anti-VEGF monoclonal antibody - Toagosei; huMV 833; SMART anti-VEGF; SMART anti-VEGF monoclonal antibody

Latest Information Update: 07 May 2002

Price : $50

At a glance

  • Originator Toagosei
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 15 Feb 2001 A phase I study has been added to the Cancer pharmacodynamics and adverse events sections
  • 07 Dec 2000 Discontinued - Preclinical for Solid tumours in Japan (unspecified route)
  • 07 Dec 2000 Discontinued - Phase-I for Solid tumours in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top